Preferred Label : idecabtagene vicleucel;
CISMeF synonym : bb2121;
MeSH synonym : ide-cel;
UNII : 8PX1X7UG4D;
Origin ID : C000715380;
UMLS CUI : C3899973;
ATC code(s)
- Currated CISMeF NLP mapping
- MeSH term(s) associated for indexing
- Pharmacological action(s)
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- Cell [UMLS semantic type]
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://ansm.sante.fr/tableau-atu-rtu/abecma-260-500-x-106-cellules-dispersion-pour-perfusion
2025
false
false
false
France
French
guidelines for drug use
Idecabtagene Vicleucel
Idecabtagene Vicleucel
gene therapy
immunotherapy, adoptive
adult
multiple myeloma
recurrence
Refractory Multiple Myeloma
idecabtagene vicleucel
idecabtagene vicleucel
Recurrent Multiple Myeloma
genetic therapy
---
https://ansm.sante.fr/tableau-marr/idecabtagene-vicleucel
2025
false
false
false
France
French
guidelines for drug use
popular works
risk management
idecabtagene vicleucel
idecabtagene vicleucel
Drug-Related side effects and adverse reactions
Drug-Related side effects and adverse reactions
Cytokine Release Syndrome
drug compounding
idecabtagene vicleucel
gene therapy
immunotherapy, adoptive
idecabtagene vicleucel
continuity of patient care
nervous system diseases
infusions, intravenous
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
multiple myeloma
Cytokine Release Syndrome
Cytokine Release Syndrome
signs and symptoms
defrosting
---
https://www.has-sante.fr/jcms/p_3412521/fr/abecma-idecabtagene-vicleucel-myelome-multiple
https://www.has-sante.fr/jcms/p_3412521/en/abecma-idecabtagene-vicleucel-myelome-multiple
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
idecabtagene vicleucel
infusions, intravenous
Antineoplastic Agents, Immunological
evaluation of the transparency committee
idecabtagene vicleucel
multiple myeloma
---
https://www.has-sante.fr/jcms/p_3548873/fr/abecma-idecabtagene-vicleucel-myelome-multiple
2024
false
false
false
France
Refractory Multiple Myeloma
adult
evaluation of the transparency committee
multiple myeloma
idecabtagene vicleucel
---
https://www.has-sante.fr/jcms/p_3536249/fr/abecma-idecabtagene-vicleucel-myelome-multiple
2024
false
false
false
France
adult
insurance, health, reimbursement
treatment outcome
package leaflet
summary of product characteristics
Recurrent Multiple Myeloma
Refractory Multiple Myeloma
Antineoplastic Agents, Immunological
idecabtagene vicleucel
Multiple myeloma progression
guidelines for drug use
evaluation of the transparency committee
multiple myeloma
idecabtagene vicleucel
---
https://www.has-sante.fr/jcms/p_3449177/fr/abecma-idecabtagene-vicleucel-myelome-multiple
2023
France
evaluation of the transparency committee
Myeloma
idecabtagene vicleucel
multiple myeloma
idecabtagene vicleucel
multiple myeloma
Myeloma
---
https://www.has-sante.fr/jcms/p_3308681/fr/abecma-idecabtagene-vicleucel
2022
false
false
false
France
infusions, intravenous
treatment outcome
insurance, health, reimbursement
Antineoplastic Agents, Immunological
immunotherapy, adoptive
adult
multiple myeloma
Recurrent Multiple Myeloma
Triple-Class Refractory Multiple Myeloma
idecabtagene vicleucel
evaluation of the transparency committee
idecabtagene vicleucel
---
